Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia
- Registration Number
- NCT00786305
- Lead Sponsor
- Groupe Hospitalier Pitie-Salpetriere
- Brief Summary
Pseudomonas aeruginosa is one of the major causative microorganisms of ventilator-associated pneumonia often resistant to antibiotics. In experimental models, nebulization of antibiotics delivers high lung tissue concentrations of antibiotics in infected lungs and increases lung bacterial killing. The aim of the study is to assess the efficiency of nebulized ceftazidime and amikacin in the treatment of pneumonia caused by Pseudomonas aeruginosa in ventilated patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Male or female >18 years old, ventilator associated pneumonia caused by pseudomonas aeruginosa
- Written informed consent provided by the relatives
Exclusion Criteria
- Pseudomonas aeruginosa resistant to ceftazidime and amikacin
- Pseudomonas aeruginosa pneumonia associated with other infections requiring intravenous treatment
- Severe septic shock and severe hypoxemia
- Allergy to ceftazidime or amikacin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1: nebulized ceftazidime and amikacin ceftazidime and amikacin - 2: intravenous ceftazidime and amikacin ceftazidime and amikacin -
- Primary Outcome Measures
Name Time Method Bacterial killing 14 days
- Secondary Outcome Measures
Name Time Method Changes of lung aeration 8 days
Trial Locations
- Locations (1)
Intensive care unit, Department of anesthesiology, La pitie-Salpetriere hospital
🇫🇷Paris, France